Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomemlar injury

Jonathan P. Tolins, Leopoldo Raij

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The protective effect of converting enzyme inhibitors in experimental hypertensive glomerular injury is associated with decreased systemic arterial and glomerular capillary pressure. Although calcium channel blockers effectively lower systemic blood pressure, their effect on glomerular capillary pressure and on hypertensive glomerular injury is uncertain. We compared equihypotensive treatment with the calcium antagonist TA 3090 or the converting enzyme inhibitor captopril in post-salt hypertensive Dahl salt-sensitive (DS) rats for up to 5 weeks after five sixths nephrectomy. Before the nephrectomy, all rats demonstrated hypertension (mean 177 mm Hg), proteinuria (mean 175 mg/day), and mild glomerulosclerosis (mean injury score 35). Rats treated with captopril or TA 3090 demonstrated a significant and equivalent decrease in systolic blood pressure compared with untreated rats at 2,3, and 5 weeks after five sixths nephrectomy; however, only captopril reduced proteinuria. Final proteinuria was actually increased in rats treated with TA 3090 compared with untreated rats. Glomerular injury score was significantly decreased in captopril-treated compared with untreated rats at 2 weeks (33±9 versus 117±10, p<0.05) and 5 weeks (46±9 versus 94±24, p<0.05), whereas treatment with TA 3090 delayed but did not prevent progressive glomerular injury (2-week score 35±7, p<0.05 versus untreated; 5-week score 109±19, p=NS versus untreated). Thus, in hypertensive DS rats after subtotal nephrectomy, treatment with a converting enzyme inhibitor reduced systemic blood pressure, proteinuria, and glomerulosclerosis. However, equihypotensive treatment with a calcium channel blocker did not reduce proteinuria and delayed but did not prevent glomerulosclerosis. Thus, in the rat similar reductions in systemic blood pressure with these two classes of agents have disparate effects on the progression of chronic renal failure.

Original languageEnglish
Pages (from-to)452-461
Number of pages10
JournalHypertension
Volume16
Issue number4
StatePublished - Oct 1 1990
Externally publishedYes

Fingerprint

Calcium Channel Blockers
Enzyme Inhibitors
Proteinuria
Captopril
Nephrectomy
Wounds and Injuries
Blood Pressure
Inbred Dahl Rats
Pressure
Chronic Kidney Failure
Salts
Hypertension
Calcium
clentiazem

Keywords

  • Angiotensin converting enzyme inhibitors
  • Calcium channel blockers
  • Glomerular function
  • Glomerulosclerosis
  • Proteinuria
  • Renal hypertension

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomemlar injury. / Tolins, Jonathan P.; Raij, Leopoldo.

In: Hypertension, Vol. 16, No. 4, 01.10.1990, p. 452-461.

Research output: Contribution to journalArticle

Tolins, Jonathan P. ; Raij, Leopoldo. / Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomemlar injury. In: Hypertension. 1990 ; Vol. 16, No. 4. pp. 452-461.
@article{99e5f1361ca74b4a89446e806642e581,
title = "Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomemlar injury",
abstract = "The protective effect of converting enzyme inhibitors in experimental hypertensive glomerular injury is associated with decreased systemic arterial and glomerular capillary pressure. Although calcium channel blockers effectively lower systemic blood pressure, their effect on glomerular capillary pressure and on hypertensive glomerular injury is uncertain. We compared equihypotensive treatment with the calcium antagonist TA 3090 or the converting enzyme inhibitor captopril in post-salt hypertensive Dahl salt-sensitive (DS) rats for up to 5 weeks after five sixths nephrectomy. Before the nephrectomy, all rats demonstrated hypertension (mean 177 mm Hg), proteinuria (mean 175 mg/day), and mild glomerulosclerosis (mean injury score 35). Rats treated with captopril or TA 3090 demonstrated a significant and equivalent decrease in systolic blood pressure compared with untreated rats at 2,3, and 5 weeks after five sixths nephrectomy; however, only captopril reduced proteinuria. Final proteinuria was actually increased in rats treated with TA 3090 compared with untreated rats. Glomerular injury score was significantly decreased in captopril-treated compared with untreated rats at 2 weeks (33±9 versus 117±10, p<0.05) and 5 weeks (46±9 versus 94±24, p<0.05), whereas treatment with TA 3090 delayed but did not prevent progressive glomerular injury (2-week score 35±7, p<0.05 versus untreated; 5-week score 109±19, p=NS versus untreated). Thus, in hypertensive DS rats after subtotal nephrectomy, treatment with a converting enzyme inhibitor reduced systemic blood pressure, proteinuria, and glomerulosclerosis. However, equihypotensive treatment with a calcium channel blocker did not reduce proteinuria and delayed but did not prevent glomerulosclerosis. Thus, in the rat similar reductions in systemic blood pressure with these two classes of agents have disparate effects on the progression of chronic renal failure.",
keywords = "Angiotensin converting enzyme inhibitors, Calcium channel blockers, Glomerular function, Glomerulosclerosis, Proteinuria, Renal hypertension",
author = "Tolins, {Jonathan P.} and Leopoldo Raij",
year = "1990",
month = "10",
day = "1",
language = "English",
volume = "16",
pages = "452--461",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomemlar injury

AU - Tolins, Jonathan P.

AU - Raij, Leopoldo

PY - 1990/10/1

Y1 - 1990/10/1

N2 - The protective effect of converting enzyme inhibitors in experimental hypertensive glomerular injury is associated with decreased systemic arterial and glomerular capillary pressure. Although calcium channel blockers effectively lower systemic blood pressure, their effect on glomerular capillary pressure and on hypertensive glomerular injury is uncertain. We compared equihypotensive treatment with the calcium antagonist TA 3090 or the converting enzyme inhibitor captopril in post-salt hypertensive Dahl salt-sensitive (DS) rats for up to 5 weeks after five sixths nephrectomy. Before the nephrectomy, all rats demonstrated hypertension (mean 177 mm Hg), proteinuria (mean 175 mg/day), and mild glomerulosclerosis (mean injury score 35). Rats treated with captopril or TA 3090 demonstrated a significant and equivalent decrease in systolic blood pressure compared with untreated rats at 2,3, and 5 weeks after five sixths nephrectomy; however, only captopril reduced proteinuria. Final proteinuria was actually increased in rats treated with TA 3090 compared with untreated rats. Glomerular injury score was significantly decreased in captopril-treated compared with untreated rats at 2 weeks (33±9 versus 117±10, p<0.05) and 5 weeks (46±9 versus 94±24, p<0.05), whereas treatment with TA 3090 delayed but did not prevent progressive glomerular injury (2-week score 35±7, p<0.05 versus untreated; 5-week score 109±19, p=NS versus untreated). Thus, in hypertensive DS rats after subtotal nephrectomy, treatment with a converting enzyme inhibitor reduced systemic blood pressure, proteinuria, and glomerulosclerosis. However, equihypotensive treatment with a calcium channel blocker did not reduce proteinuria and delayed but did not prevent glomerulosclerosis. Thus, in the rat similar reductions in systemic blood pressure with these two classes of agents have disparate effects on the progression of chronic renal failure.

AB - The protective effect of converting enzyme inhibitors in experimental hypertensive glomerular injury is associated with decreased systemic arterial and glomerular capillary pressure. Although calcium channel blockers effectively lower systemic blood pressure, their effect on glomerular capillary pressure and on hypertensive glomerular injury is uncertain. We compared equihypotensive treatment with the calcium antagonist TA 3090 or the converting enzyme inhibitor captopril in post-salt hypertensive Dahl salt-sensitive (DS) rats for up to 5 weeks after five sixths nephrectomy. Before the nephrectomy, all rats demonstrated hypertension (mean 177 mm Hg), proteinuria (mean 175 mg/day), and mild glomerulosclerosis (mean injury score 35). Rats treated with captopril or TA 3090 demonstrated a significant and equivalent decrease in systolic blood pressure compared with untreated rats at 2,3, and 5 weeks after five sixths nephrectomy; however, only captopril reduced proteinuria. Final proteinuria was actually increased in rats treated with TA 3090 compared with untreated rats. Glomerular injury score was significantly decreased in captopril-treated compared with untreated rats at 2 weeks (33±9 versus 117±10, p<0.05) and 5 weeks (46±9 versus 94±24, p<0.05), whereas treatment with TA 3090 delayed but did not prevent progressive glomerular injury (2-week score 35±7, p<0.05 versus untreated; 5-week score 109±19, p=NS versus untreated). Thus, in hypertensive DS rats after subtotal nephrectomy, treatment with a converting enzyme inhibitor reduced systemic blood pressure, proteinuria, and glomerulosclerosis. However, equihypotensive treatment with a calcium channel blocker did not reduce proteinuria and delayed but did not prevent glomerulosclerosis. Thus, in the rat similar reductions in systemic blood pressure with these two classes of agents have disparate effects on the progression of chronic renal failure.

KW - Angiotensin converting enzyme inhibitors

KW - Calcium channel blockers

KW - Glomerular function

KW - Glomerulosclerosis

KW - Proteinuria

KW - Renal hypertension

UR - http://www.scopus.com/inward/record.url?scp=0025093206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025093206&partnerID=8YFLogxK

M3 - Article

C2 - 2210813

AN - SCOPUS:0025093206

VL - 16

SP - 452

EP - 461

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -